NCT03608605

Brief Summary

We aim to evaluate the role of conventional and advanced MRI sequences in:

  1. 1.Establishing the diagnosis of multiple sclerosis and differentiate it from its mimics.
  2. 2.Predict the prognosis and evaluate the treatment response in the first year of patients with multiple sclerosis.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2018

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 18, 2018

Completed
14 days until next milestone

First Posted

Study publicly available on registry

August 1, 2018

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2018

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2020

Completed
Last Updated

August 1, 2018

Status Verified

July 1, 2018

Enrollment Period

1.6 years

First QC Date

July 18, 2018

Last Update Submit

July 30, 2018

Conditions

Multiple Sclerosis

Outcome Measures

Primary Outcomes (1)

  • role of advanced MRI sequences in establishing the diagnosis of multiple sclerosis(MS)

    calculating the sensitivity,specificity and accuracy of diffusion tensor imaging (DTI) and dual inversion recovery(DIR) in differentiating MS from its mimics

    baseline

Secondary Outcomes (1)

  • follow up of MS patients after one year of treatment

    one year

Interventions

MRIDEVICE

magnetic resonance imaging with advanced sequences including tractography,volumetry and inversion recovery

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

All patients among those attend to Assiut university hospital with clinical symptoms suspicious of MS according to McDonald criteria 2017 with age range from (18-50 years old).

You may qualify if:

  • All patients in the study will be referred among those attend to Assuit university hospital with clinical symptoms suspicious of MS according to McDonald criteria 2017 with age range from (18-50 years old).

You may not qualify if:

  • o Any general contraindication of MRI in some cases as presence of paramagnetic substance as pacemakers or in patients with claustrophobia.
  • Patient above 50 years old.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System Diseases

Central Study Contacts

samaa el-kossi, master

CONTACT

01028820033samaa.mostafa12330@gmail.com

gehan sayed, doctorate

CONTACT

gehanseif@yahoo.com

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
assisstant lecturer

Study Record Dates

First Submitted

July 18, 2018

First Posted

August 1, 2018

Study Start

September 1, 2018

Primary Completion

April 1, 2020

Study Completion

July 1, 2020

Last Updated

August 1, 2018

Record last verified: 2018-07